Prior art — US Patent 12569490

To identify the most relevant prior art for US patent 12569490, I will search the USPTO database for the patent and examine its cited references.

The USPTO provides a Patent Public Search tool to search its database of patents and patent application publications. I will use the patent number 12569490 to perform a direct search.

USPTO Search for Patent 12569490 and Prior Art Analysis

As of April 26, 2026, a search on the USPTO Patent Public Search portal for patent number US12569490 reveals the following prior art. Since direct access to the USPTO database for a real-time extraction of all cited prior art references and their detailed descriptions isn't feasible through this interface, I will leverage the information provided in the full patent text and Google Patents for the cited references. The full patent text of US12569490B2 indicates several cross-references and claims of benefit from earlier applications, which serve as crucial prior art.

Cross-referenced Applications (Internal Prior Art):

The patent US12569490B2 explicitly states: "This application is a continuation of U.S. application Ser. No. 18/941,832, filed Nov. 8, 2024, which is a continuation of U.S. application Ser. No. 17/667,285, filed on Feb. 8, 2022, which is a continuation of U.S. application Ser. No. 17/081,694 filed on Oct. 27, 2020, which issued as U.S. Pat. No. 11,304,950 on Apr. 19, 2022, and which is a continuation of International Application No. PCT/US2019/029486 filed on Apr. 26, 2019, which claims the benefit of U.S. Provisional Patent Application No. 62/663,951, filed Apr. 27, 2018, and U.S. Provisional Patent Application No. 62/822,815, filed Mar. 23, 2019, each of which is entirely incorporated herein by reference."

These applications represent a chain of continuous prosecution, meaning their content, particularly related to the treatment of TART and OART using CRF1 antagonists, is highly relevant as prior art under 35 U.S.C. § 102.

U.S. Provisional Patent Application No. 62/663,951
- Full Citation: U.S. Provisional Patent Application No. 62/663,951
- Filing Date: April 27, 2018
- Brief Description: This is the earliest priority document cited. It would likely describe the initial concepts, compounds, and methods for treating testicular and ovarian adrenal rest tumors using CRF1 antagonists.
- Potential Anticipation (35 U.S.C. § 102): Potentially anticipates all claims (Claims 1-20) of US12569490B2 if the scope of disclosure within this provisional application is sufficiently broad and enabling. As the earliest priority, any subject matter disclosed therein would constitute prior art against later-filed claims.
U.S. Provisional Patent Application No. 62/822,815
- Full Citation: U.S. Provisional Patent Application No. 62/822,815
- Filing Date: March 23, 2019
- Brief Description: This provisional application would provide further details, refinements, or additional embodiments related to the treatment methods and CRF1 antagonist compounds for TART and OART, building upon the earlier provisional application.
- Potential Anticipation (35 U.S.C. § 102): Potentially anticipates all claims (Claims 1-20) of US12569490B2 for any subject matter disclosed therein that is not present in the earlier provisional, assuming it was filed before the invention date of the currently examined claims.
International Application No. PCT/US2019/029486
- Full Citation: International Application No. PCT/US2019/029486
- Filing Date: April 26, 2019
- Brief Description: This PCT application is a continuation of the two provisional applications and would consolidate and expand upon their disclosures for international protection. It would contain detailed descriptions of the CRF1 antagonists, their formulations, and methods of treating TART and OART.
- Potential Anticipation (35 U.S.C. § 102): Potentially anticipates all claims (Claims 1-20) of US12569490B2, particularly if it contains additional enabling disclosure or claims that predate the invention date of any new subject matter in the current patent.
U.S. Pat. No. 11,304,950
- Full Citation: U.S. Pat. No. 11,304,950
- Issue Date: April 19, 2022
- Brief Description: This patent is explicitly stated to be an issued patent from a continuation chain leading to US12569490B2. It would cover aspects of the methods for treating testicular and ovarian adrenal rest tumors using CRF1 antagonists, likely including compounds of structural Formula (I).
- Potential Anticipation (35 U.S.C. § 102): As an issued patent in the direct lineage, it would likely anticipate many, if not all, of the independent claims (Claims 1 and 10) of US12569490B2, especially if the claims in US11304950B2 cover the core method of administering a CRF1 antagonist or compounds of Formula (I) for treating TART/OART. Any features or combinations claimed in US12569490B2 that are directly disclosed and enabled in US11304950B2 would be anticipated.
U.S. application Ser. No. 17/081,694
- Full Citation: U.S. application Ser. No. 17/081,694
- Filing Date: October 27, 2020
- Brief Description: This is the application that issued as U.S. Pat. No. 11,304,950. Its content would therefore be identical to that patent for purposes of prior art analysis.
- Potential Anticipation (35 U.S.C. § 102): As the application leading to US11304950B2, it would anticipate the same claims as the issued patent.
U.S. application Ser. No. 17/667,285
- Full Citation: U.S. application Ser. No. 17/667,285
- Filing Date: February 8, 2022
- Brief Description: This is a continuation of the application that issued as US11304950B2. It would contain substantially the same disclosure, but potentially with different claims or minor adjustments to the specification.
- Potential Anticipation (35 U.S.C. § 102): Highly likely to anticipate claims (Claims 1-20) that are present in both applications, especially those broadly defining the use of CRF1 antagonists or compounds of Formula (I) for TART/OART treatment.
U.S. application Ser. No. 18/941,832
- Full Citation: U.S. application Ser. No. 18/941,832
- Filing Date: November 8, 2024
- Brief Description: This is the immediate parent continuation application to US12569490B2. Its disclosure would be highly similar, if not identical, to the present patent.
- Potential Anticipation (35 U.S.C. § 102): Given its direct continuation status and filing date prior to the issue date of US12569490B2, it would very likely anticipate all claims (Claims 1-20) if the subject matter of those claims was sufficiently disclosed and enabled within this application.

Other Potential Prior Art (External Citations - not detailed in the provided text):

To provide a comprehensive analysis of external prior art, a direct search of the USPTO database for the "Cited By" section of US12569490B2 would be necessary. Without this direct access, I can only rely on the self-declared internal prior art mentioned in the patent. For a full analysis, one would navigate to the patent on the USPTO Patent Public Search portal (or Google Patents, as the Google Patents page for US12569490B2 shows a "Prior art" section with keywords, but does not list specific external patent or non-patent literature citations directly in the provided text).

Based on the title and abstract, general areas of prior art would likely include:

Methods for treating congenital adrenal hyperplasia (CAH).
Compounds and pharmaceutical compositions that act as corticotropin-releasing factor type-1 (CRF1) antagonists.
Medical treatments, both surgical and non-surgical, for testicular adrenal rest tumors (TART) and ovarian adrenal rest tumors (OART).
Research on the pathophysiology of TART and OART, particularly their dependence on ACTH.

Without specific external citations listed in the provided patent text, it is not possible to detail other relevant prior art references at this time.